In this study, we use genetic, biochemical, and pharmacological approaches to investigate the role of wild-type IDH2 in breast cancer, and found that this enzyme plays a critical role in the survival of triple-negative breast cancer (TNBC) cells by promoting the reductive TCA cycle and keeping α-KG at the normal range. Here, IDH2 is linked to triple-negative breast carcinoma.